Omeros Corporation has announced that OMS824, its phosphodiesterase 10 inhibitor, has received an orphan drug designation from the FDA for the treatment of patients with Huntington's disease.
http://www.formkit.com/news/DailyDetail.cfm?chosen=67847
http://www.formkit.com/news/DailyDetail.cfm?chosen=67847
No comments:
Post a Comment